Warm autoimmune hemolytic anemia
ICD-10 D59.11 is a billable code used to indicate a diagnosis of warm autoimmune hemolytic anemia.
Warm autoimmune hemolytic anemia (AIHA) is a type of hemolytic anemia characterized by the premature destruction of red blood cells due to the presence of autoantibodies that react at body temperature (37°C). This condition can be idiopathic or secondary to other diseases such as lymphoproliferative disorders, autoimmune diseases (like lupus), or infections. Patients typically present with symptoms of anemia, including fatigue, pallor, jaundice, and splenomegaly. Laboratory findings often reveal a positive direct Coombs test, elevated reticulocyte count, and increased levels of indirect bilirubin. The pathophysiology involves the binding of antibodies to red blood cells, leading to their destruction by macrophages in the spleen and liver. Treatment options may include corticosteroids, immunosuppressive agents, or splenectomy in severe cases. Understanding the nuances of this condition is crucial for accurate coding and management.
Detailed lab results, treatment plans, and follow-up notes are essential.
Diagnosis and management of AIHA, monitoring response to treatment.
Ensure that all autoimmune tests and their results are documented clearly.
Documentation of underlying autoimmune conditions and their management.
Patients with AIHA secondary to lupus or other autoimmune disorders.
Document the relationship between the autoimmune disorder and hemolytic anemia.
Used to evaluate anemia and monitor treatment response.
Document the reason for the CBC and reticulocyte count.
Hematologists should ensure all relevant lab results are included.
The primary cause is the production of autoantibodies that target red blood cells, leading to their destruction. This can be idiopathic or secondary to other conditions.
